Patents by Inventor Yossef Av-Gay
Yossef Av-Gay has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 11890421Abstract: The invention provides a method of treating a subject having a medical condition associated with a pathogenic microorganism, the method comprising administering to said subject a potentiating effective amount of nitric oxide; and administering to said subject a therapeutically effective amount of an antimicrobial agent, wherein said antimicrobial agent is other than said nitric oxide.Type: GrantFiled: February 11, 2020Date of Patent: February 6, 2024Assignee: BEYOND AIR LTDInventors: Yossef Av-Gay, David Greenberg, Asher Tal
-
Publication number: 20230051940Abstract: In one embodiment, the present invention provides a system to deliver at least one therapeutic gas to a spontaneously breathing patient, wherein the rate of delivery of the at least one therapeutic gas exceeds the patient's inspiratory flow rate, and the amount of the at least one therapeutic gas that is wasted is minimized or eliminated.Type: ApplicationFiled: August 13, 2022Publication date: February 16, 2023Inventors: Curtis Figley, Einav Levi, Atai Ophir, Yossef Av-Gay
-
Patent number: 11452827Abstract: In one embodiment, the present invention provides a system to deliver at least one therapeutic gas to a spontaneously breathing patient, wherein the rate of delivery of the at least one therapeutic gas exceeds the patient's inspiratory flow rate, and the amount of the at least one therapeutic gas that is wasted is minimized or eliminated.Type: GrantFiled: January 27, 2017Date of Patent: September 27, 2022Assignee: BEYOND AIR LTDInventors: Curtis Figley, Einav Levi, Atai Ophir, Yossef Av-Gay
-
Patent number: 11337863Abstract: A nitric oxide gas-releasing conduit configured for surgical implantation through a patient's tympanic membrane. The nitric oxide gas-releasing conduit comprises a gas-permeable cured resin material configured for releasably sequestering therein gas. The gas-permeable cured resin material is charged with nitric oxide gas. The nitric oxide gas-releasing conduit may be optionally coated with an antimicrobial gas-releasing composition. The gas-releasing coating composition may be configured to release nitric oxide.Type: GrantFiled: June 18, 2019Date of Patent: May 24, 2022Assignee: ENOX (ISRAEL) LTD.Inventors: Yossef Av-Gay, David Greenberg
-
Publication number: 20220047623Abstract: A method of treating a human subject which is effected by intermittent inhalation of gaseous nitric oxide at a concentration of at least 160 ppm is disclosed. The method can be utilized for treating a human subject suffering from, or prone to suffer from, a disease or disorder that is manifested in the respiratory tract, or from a disease or disorder that can be treated via the respiratory tract. The disclosed method can be effected while monitoring one or more of on-site and off-site parameters such as vital signs, methemoglobin levels, pulmonary function parameters, blood chemistry and hematological parameters, blood coagulation parameters, inflammatory marker levels, liver and kidney function parameters and vascular endothelial activation parameters, such that no substantial deviation from a baseline in seen in one or more of the monitored parameters.Type: ApplicationFiled: August 25, 2021Publication date: February 17, 2022Inventors: Yossef Av-Gay, Christopher C. Miller, David Greenberg
-
Publication number: 20210205565Abstract: In some embodiments, the present invention provides a method for treating bronchiolitis in an infant in need thereof, wherein the wherein the method comprises repeatedly administering to the infant a gas mixture comprising nitric oxide at a concentration from about 144 to about 176 ppm for a first period of time, followed by a gas mixture containing no nitric oxide for a second period of time, wherein the administration is repeated for a time sufficient to: a) reduce the length of time of hospitalization required to achieve oxygen saturation greater than or equal to 92% in room air, compared an infant that is not subjected to the repeated administration of nitric oxide; b) reduce the length of time of hospitalization required to achieve a clinical score of less than or equal to 5, compared an infant that is not subjected to the repeated administration of nitric oxide; c) reduce the length of time of hospitalization required to be discharged, compared an infant that is not subjected to the repeated adminisType: ApplicationFiled: January 27, 2021Publication date: July 8, 2021Inventors: Yossef Av-Gay, David Greenberg, Asher Tal
-
Publication number: 20200276229Abstract: A method of treating a human subject which is effected by intermittent inhalation of gaseous nitric oxide at a concentration of at least 160 ppm is disclosed. The method can be utilized for treating a human subject suffering from, or prone to suffer from, a disease or disorder that is manifested in the respiratory tract, or from a disease or disorder that can be treated via the respiratory tract. The disclosed method can be effected while monitoring one or more of on-site and off-site parameters such as vital signs, methemoglobin levels, pulmonary function parameters, blood chemistry and hematological parameters, blood coagulation parameters, inflammatory marker levels, liver and kidney function parameters and vascular endothelial activation parameters, such that no substantial deviation from a baseline in seen in one or more of the monitored parameters.Type: ApplicationFiled: May 20, 2020Publication date: September 3, 2020Inventors: Yossef Av-Gay, Christopher C. Miller, David Greenberg
-
Publication number: 20200246573Abstract: In some embodiments, the present invention provides a method for treating bronchiolitis in an infant in need thereof, wherein the wherein the method comprises repeatedly administering to the infant a gas mixture comprising nitric oxide at a concentration from about 144 to about 176 ppm for a first period of time, followed by a gas mixture containing no nitric oxide for a second period of time, wherein the administration is repeated for a time sufficient to: a) reduce the length of time of hospitalization required to achieve oxygen saturation greater than or equal to 92% in room air, compared an infant that is not subjected to the repeated administration of nitric oxide; b) reduce the length of time of hospitalization required to achieve a clinical score of less than or equal to 5, compared an infant that is not subjected to the repeated administration of nitric oxide; c) reduce the length of time of hospitalization required to be discharged, compared an infant that is not subjected to the repeated adminisType: ApplicationFiled: February 11, 2020Publication date: August 6, 2020Inventors: Yossef Av-Gay, David Greenberg, Asher Tal
-
Publication number: 20200215102Abstract: A method of treating a human subject which is effected by intermittent inhalation of gaseous nitric oxide at a concentration of at least 160 ppm is disclosed. The method can be utilized for treating a human subject suffering from, or prone to suffer from, a disease or disorder that is manifested in the respiratory tract, or from a disease or disorder that can be treated via the respiratory tract. The disclosed method can be effected while monitoring one or more of on-site and off-site parameters such as vital signs, methemoglobin levels, pulmonary function parameters, blood chemistry and hematological parameters, blood coagulation parameters, inflammatory marker levels, liver and kidney function parameters and vascular endothelial activation parameters, such that no substantial deviation from a baseline in seen in one or more of the monitored parameters.Type: ApplicationFiled: March 2, 2020Publication date: July 9, 2020Inventors: Yossef Av-Gay, Christopher C. Miller, David Greenberg
-
Publication number: 20190298575Abstract: A nitric oxide gas-releasing conduit configured for surgical implantation through a patient's tympanic membrane. The nitric oxide gas-releasing conduit comprises a gas-permeable cured resin material configured for releasably sequestering therein gas. The gas-permeable cured resin material is charged with nitric oxide gas. The nitric oxide gas-releasing conduit may be optionally coated with an antimicrobial gas-releasing composition. The gas-releasing coating composition may be configured to release nitric oxide.Type: ApplicationFiled: June 18, 2019Publication date: October 3, 2019Inventors: Yossef AV-GAY, David GREENBERG
-
Patent number: 10350112Abstract: A nitric oxide gas-releasing conduit configured for surgical implantation through a patient's tympanic membrane. The nitric oxide gas-releasing conduit comprises a gas-permeable cured resin material configured for releasably sequestering therein gas. The gas-permeable cured resin material is charged with nitric oxide gas. The nitric oxide gas-releasing conduit may be optionally coated with an antimicrobial gas-releasing composition. The gas-releasing coating composition may be configured to release nitric oxide.Type: GrantFiled: June 29, 2010Date of Patent: July 16, 2019Assignee: ENOX (ISRAEL) LTD.Inventors: Yossef Av-Gay, David Greenberg
-
Publication number: 20190091425Abstract: In one embodiment, the present invention provides a system to deliver at least one therapeutic gas to a spontaneously breathing patient, wherein the rate of delivery of the at least one therapeutic gas exceeds the patient's inspiratory flow rate, and the amount of the at least one therapeutic gas that is wasted is minimized or eliminated.Type: ApplicationFiled: January 27, 2017Publication date: March 28, 2019Inventors: Curtis Figley, Einav Levi, Atai Ophir, Yossef Av-Gay
-
Publication number: 20180243526Abstract: The present invention provides a method for treating bronchiolitis in an infant in need thereof, wherein the method comprises repeatedly administering to the infant a gas mixture comprising nitric oxide at a concentration from about 144 to about 176 ppm for a first period of time, followed by a gas mixture containing no nitric oxide for a second period of time, wherein the administration is repeated for a time sufficient to: a) reduce the length of time of hospitalization required to achieve oxygen saturation greater than or equal to 92% in room air; b) reduce the length of time of hospitalization required to achieve a clinical score of less than or equal to 5; c) reduce the length of time of hospitalization required to be discharged; or d) any combination thereof, as compared to an infant that is not subjected to the repeated administration of nitric oxide.Type: ApplicationFiled: September 9, 2016Publication date: August 30, 2018Inventors: Yossef Av-Gay, David Greenberg, Asher Tal
-
Patent number: 10039781Abstract: A method of treating a human subject which is effected by intermittent breathing cycle-coordinated pulse delivery inhalation of gaseous nitric oxide at a concentration of at least 160 ppm, or at a load per cycle of 80 ppm-hour, is disclosed. The method can be utilized for treating a human subject suffering from, or prone to suffer from, a disease or disorder that is manifested in the respiratory tract, or from a disease or disorder that can be treated via the respiratory tract. The disclosed method can be effected while monitoring one or more of on-site and off-site parameters such as vital signs, methemoglobin levels, pulmonary function parameters, blood chemistry and hematological parameters, blood coagulation parameters, inflammatory marker levels, liver and kidney function parameters and vascular endothelial activation parameters, such that no substantial deviation from a baseline in seen in one or more of the monitored parameters.Type: GrantFiled: March 24, 2016Date of Patent: August 7, 2018Assignee: AIT THERAPEUTICS, INC.Inventors: Yossef Av-Gay, David Greenberg, Einav Levi
-
Publication number: 20180133246Abstract: A method of treating a human subject which is effected by intermittent inhalation of gaseous nitric oxide at a concentration of at least 160 ppm is disclosed. The method can be utilized for treating a human subject suffering from, or prone to suffer from, a disease or disorder that is manifested in the respiratory tract, or from a disease or disorder that can be treated via the respiratory tract. The disclosed method can be effected while monitoring one or more of on-site and off-site parameters such as vital signs, methemoglobin levels, pulmonary function parameters, blood chemistry and hematological parameters, blood coagulation parameters, inflammatory marker levels, liver and kidney function parameters and vascular endothelial activation parameters, such that no substantial deviation from a baseline in seen in one or more of the monitored parameters.Type: ApplicationFiled: November 1, 2017Publication date: May 17, 2018Inventors: Yossef Av-Gay, Christopher C. Miller, David Greensberg
-
Publication number: 20180125883Abstract: A method of treating a human subject which is effected by intermittent inhalation of gaseous nitric oxide at a concentration of at least 160 ppm is disclosed. The method can be utilized for treating a human subject suffering from, or prone to suffer from, a disease or disorder that is manifested in the respiratory tract, or from a disease or disorder that can be treated via the respiratory tract. The disclosed method can be effected while monitoring one or more of on-site and off-site parameters such as vital signs, methemoglobin levels, pulmonary function parameters, blood chemistry and hematological parameters, blood coagulation parameters, inflammatory marker levels, liver and kidney function parameters and vascular endothelial activation parameters, such that no substantial deviation from a baseline in seen in one or more of the monitored parameters.Type: ApplicationFiled: September 20, 2017Publication date: May 10, 2018Inventors: Yossef Av-Gay, Christopher C. Miller, David Greenberg
-
Patent number: 9814623Abstract: A nitric oxide gas-releasing conduit configured for surgical implantation through a patient's tympanic membrane. The nitric oxide gas-releasing conduit comprises a gas-permeable cured resin material configured for releasably sequestering therein gas. The gas-permeable cured resin material is charged with nitric oxide gas. The nitric oxide gas-releasing conduit may be optionally coated with an antimicrobial gas-releasing composition. The gas-releasing coating composition may be configured to release nitric oxide.Type: GrantFiled: June 29, 2010Date of Patent: November 14, 2017Assignee: ENOX (ISRAEL) LTD.Inventors: Yossef Av-Gay, David Greenberg
-
Publication number: 20170239289Abstract: The present invention provides a method for treating a disease in a human subject in need thereof, wherein the disease is selected from the group consisting of inflammation, bronchiolitis and cystic fibrosis, and wherein the method comprises repeatedly administering to the human subject a gas mixture comprising nitric oxide at a concentration from about 144 to about 176 ppm for a first period of time, followed by a gas mixture containing no nitric oxide for a second period of time, wherein the administration is repeated for a time sufficient to: a) reduce the level of at least one inflammatory biomarker in the human subject when compared to the level of the inflammatory biomarker prior to the administration; b) reduce the microbial density by 1 to 2 log units as measured by colony forming units in the human subject when compared to the microbial density prior to the administration; or c) a combination thereof.Type: ApplicationFiled: August 24, 2015Publication date: August 24, 2017Applicant: Advanced Inhalation Therapies (AIT) Ltd.Inventors: Yossef Av-Gay, David Greenberg, Racheli Vizman
-
Publication number: 20170143758Abstract: A method of treating a human subject which is effected by intermittent inhalation of gaseous nitric oxide at a concentration of at least 160 ppm is disclosed. The method can be utilized for treating a human subject suffering from, or prone to suffer from, a disease or disorder that is manifested in the respiratory tract, or from a disease or disorder that can be treated via the respiratory tract. The disclosed method can be effected while monitoring one or more of on-site and off-site parameters such as vital signs, methemoglobin levels, pulmonary function parameters, blood chemistry and hematological parameters, blood coagulation parameters, inflammatory marker levels, liver and kidney function parameters and vascular endothelial activation parameters, such that no substantial deviation from a baseline in seen in one or more of the monitored parameters.Type: ApplicationFiled: January 4, 2017Publication date: May 25, 2017Applicant: Advanced Inhalation Therapies (AIT) Ltd.Inventors: David Greenberg, Yossef Av-Gay
-
Publication number: 20170065631Abstract: The present invention relates to a method of treating a human subject suffering from a disease or disorder that is manifested in the respiratory tract or a disease or disorder that can be treated via the respiratory tract, the disease or disorder being associated with a nosocomial infection, the method including subjecting the subject to intermittent inhalation of gNO at a concentration of at least 160 ppm, thereby treating the disease or disorder.Type: ApplicationFiled: September 22, 2016Publication date: March 9, 2017Applicant: Advanced Inhalation Therapies (AIT) Ltd.Inventors: Yossef Av-Gay, David Greenberg, Racheli Vizman